dupilumab

Overview

Dupilumab is a fully human monoclonal antibody used as a targeted therapy for type 2 inflammatory diseases. Its principal mechanism is blockade of interleukin-4 receptor alpha, which inhibits signaling by interleukin-4 and interleukin-13, two central cytokines in type 2 immune responses. By dampening this pathway, dupilumab reduces inflammatory activity that contributes to diseases such as atopic dermatitis, asthma, and eosinophilic esophagitis.

Clinically, dupilumab is notable for its broad use across multiple immune-mediated conditions driven by type 2 inflammation. Recent research continues to evaluate its effectiveness, safety, and comparative performance against other therapies, while also examining adverse effects such as ocular surface disease and eosinophilia. It is also being studied in special populations, including young children and patients with complex comorbid inflammatory disease.

Focus of Latest Publications

Recent publications demonstrate dupilumab's effectiveness across multiple type 2 inflammatory conditions in diverse clinical settings. In chronic spontaneous urticaria, a real-world multicentre cohort study of 51 patients showed that 69.7% achieved well-controlled disease at week 24, with response rates improving to 90.5% at week 52. Notably, dupilumab provided clinical benefit in most omalizumab-experienced patients, though prior nonresponders to omalizumab showed lower response rates (40% versus 85%). In eosinophilic esophagitis, real-world analysis of 336 patients across seven Austrian centres identified dupilumab in 12.2% of cases, predominantly as second-line therapy for patients with inadequate response to topical corticosteroids (59%) or intolerant to standard treatments (24%); 97.6% of dupilumab-treated patients remained on therapy at final follow-up.

Dupilumab's clinical utility extends to challenging settings including immune checkpoint inhibitor-induced bullous pemphigoid, where 94.74% of 19 patients achieved clinical response with 84.21% attaining complete remission. Among these patients, 82.35% discontinued systemic corticosteroids following dupilumab initiation, and notably, 61.11% were able to continue or reintroduce checkpoint inhibitor therapy—an important consideration for preserving oncological outcomes. In pediatric populations, dupilumab demonstrates safety and efficacy in severe atopic dermatitis across infants and young children (6 months to 5 years), and extends to atopic dermatitis and eosinophilic esophagitis in pediatric liver transplant recipients, conditions arising from tacrolimus-induced T helper 2 cell predominance.

Beyond clinical response, real-world studies provide mechanistic and comparative insights. In atopic dermatitis patients treated with dupilumab, seasonal variation in immune responses persists despite IL-4/IL-13 blockade; winter months showed elevated stimulated interferon-gamma, tumor necrosis factor-alpha, interleukin-2, and interleukin-6, indicating preserved inducible TH1 and innate immune activity. Comparisons with upadacitinib reveal distinct tolerability profiles: while dupilumab is associated with ocular surface disease, JAK inhibitors may present a more favorable ocular safety profile. Dupilumab was well tolerated across indications, with predominantly mild adverse events reported; treatment durability remained high in real-world populations, with most patients continuing therapy when clinical response was achieved. These findings collectively support dupilumab's role as an effective maintenance therapy for multiple type 2 inflammatory conditions, particularly in treatment-refractory populations and specialized clinical contexts.

Key Publications

• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42403314)
• NEWJul Dupilumab Is Safe and Efficacious for Treatment of Eosinophilic Esophagitis and Atopic Dermatitis in Pediatric Liver Transplant Recipients: A Case Series. (Pediatric transplantation, 2026, PMID 42351377): "Dupilumab, a monoclonal antibody that downregulates interleukin-4, interleukin-13, and the T helper 2 cell pathway, is effective for atopic dermatitis and eosinophilic esophagitis, though there is a paucity of data regarding its use and safety in pediatric liver transplant recipients."
• NEWJun Seasonal variation in cytokine profiles in atopic dermatitis patients treated with dupilumab. (Journal of immunotoxicology, 2026, PMID 42360862): "This study examined seasonal variation in plasma cytokines in adults with AD treated with dupilumab (N=20), AD patients without systemic therapy (N=15), and healthy controls (N=34)."
• NEWJun Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry. (Advances in therapy, 2026, PMID 42268495): "Dupilumab, a fully human monoclonal antibody, blocks the receptors for interleukins 4/13, key and central drivers of type 2 inflammation."
• Jun Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (The Journal of dermatological treatment, 2026, PMID 42223292): "using data from the 24-week Heads Up trial comparing dupilumab versus upadacitinib in adults with moderate-to-severe AD."
• May Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). (Dermatology and therapy, 2026, PMID 42213297): "This study aimed to characterise temporal patterns of clinical response in patients with AD treated with dupilumab or upadacitinib in routine clinical practice."
• May Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series. (Acta dermato-venereologica, 2026, PMID 42163825): "Dupilumab, a monoclonal antibody that blocks IL-4/IL-13 signalling, represents a promising alternative, offering effective disease control with an improved safety profile."
• May Treatment patterns of eosinophilic esophagitis in the biologic era-a real-world analysis. (Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2026, PMID 42119037): "Forty-one (12.2%) patients received a treatment with dupilumab of whom only one as first line treatment (because of multiple type 2 inflammatory diseases) and the majority as second line treatment (57.5%)."
• May Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment. (The Journal of dermatological treatment, 2026, PMID 42100982): "Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease."
• May Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP Program. (Dermatitis : contact, atopic, occupational, drug, 2026, PMID 42095284): "Real-world evidence on the long-term use of dupilumab in very young children with moderate-to-severe atopic dermatitis (AD) remains limited."